Anandamidia

Anandamidia is a term that does not correspond to a widely recognized substance in scientific literature. In many contexts it appears to be a misspelling or regional form of anandamide, also called N-arachidonoylethanolamide, the principal endogenous ligand of the endocannabinoid system.

Anandamide is a fatty acid amide derived from arachidonic acid. It binds to cannabinoid receptors CB1 and CB2, especially abundant in the brain, where it modulates neurotransmitter release and synaptic plasticity. It is synthesized on demand in response to cellular signals, and its signaling is terminated mainly by enzymatic hydrolysis via fatty acid amide hydrolase (FAAH).

In mammals, endocannabinoids regulate pain sensitivity, mood, appetite, memory, and neuroprotection. Anandamide signaling influences reward, stress response, and inflammatory processes. Disruptions in endocannabinoid signaling have been linked to obesity, mood disorders, and neurodegenerative conditions; pharmacological research targets FAAH inhibitors or cannabinoid receptors.

Anandamide was identified in 1992 by researchers including Devane and Mechoulam as a brain constituent that binds to cannabinoid receptors.

Given the ambiguity of the term "anandamidia," readers should verify the intended reference; if you mean anandamide, the foregoing summary describes its biology.